Purple Biotech (PPBT) Short term Debt (2015 - 2016)
Purple Biotech (PPBT) posted quarterly Short term Debt of $548000.0 for Q4 2016, little changed year-over-year from $549000.0 in Q1 2016, and little changed quarter-over-quarter from $549000.0 in Q4 2015.
Purple Biotech (PPBT) Short term Debt (2015 - 2016) Analysis & Trends
Purple Biotech (PPBT) has reported Short term Debt for 2 consecutive years, with $548000.0 the latest figure, recorded in Q4 2016.
- In Q4 2016, Short term Debt changed 0.18% year-over-year to $548000.0; the TTM figure through Dec 2016 stood at $548000.0 (changed 0.18% YoY), while the FY2016 annual figure was $548000.0, changed 0.18% from the prior year.
- Short term Debt held at $548000.0 in Q4 2016 per PPBT's latest filing, from $549000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $549000.0 in Q4 2015 and bottomed at $548000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Purple Biotech | 133.62 | 133.62 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 548,000.00 |
| Dec 31, 2015 | 549,000.00 |